CU
CU2.F Cerus Corporation
- Market cap
- EUR 382M
- P/E
- -
- P/B
- 5.48x
- ROE
- -9.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CU2.F undervalued?
Graham numberThe Graham number of Cerus Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cerus Corporation fundamental analysis
No fundamental analysis for Cerus Corporation yet.
Cerus Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cerus Corporation
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is …
Full company profileCerus Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cerus Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 39.3M | 51.3M | 76.1M | 93.8M | 114M | 160M | 162M | 156M | 180M | 206M | 225M |
| Gross Profit | 19.0M | 28.8M | 44.4M | 60.4M | 73.1M | 96.0M | 87.1M | 86.4M | 99.5M | 112M | 117M |
| Operating Income | -61.3M | -57.5M | -55.0M | -66.2M | -58.3M | -48.9M | -34.1M | -26.3M | -14.2M | -8.68M | -2.44M |
| EBITDA | - | -51.9M | -51.9M | -62.5M | -52.7M | -46.0M | -33.5M | -26.3M | -10.0M | -5.51M | 1.59M |
| Net Income | -62.9M | -60.6M | -57.6M | -71.2M | -59.9M | -54.4M | -42.8M | -37.5M | -20.9M | -15.6M | -6.84M |
| EPS | - | -0.52 | -0.42 | -0.49 | -0.36 | -0.31 | -0.24 | -0.21 | -0.11 | -0.08 | -0.03 |
| Balance Sheet | |||||||||||
| Total Assets | 103M | 98.2M | 163M | 166M | 221M | 237M | 218M | 198M | 201M | 222M | 205M |
| Total Liabilities | 45.7M | 59.3M | 78.9M | 108M | 118M | 152M | 150M | 144M | 144M | 157M | 128M |
| Shareholders' Equity | 57.8M | 38.9M | 84.5M | 57.1M | 104M | 84.6M | 67.6M | 52.7M | 56.1M | 64.2M | 75.7M |
| Cash & Short-term Investments | 22.6M | 13.7M | 28.9M | 35.0M | 36.6M | 48.8M | 35.6M | 11.6M | 20.3M | 20.0M | 16.4M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -53.5M | -52.2M | -31.2M | -65.5M | -41.8M | -33.9M | -25.6M | -43.2M | 11.4M | 4.84M | -3.60M |
| Capital Expenditure | 563K | 353K | 1.14M | 8.94M | 1.62M | 910K | 2.00M | 4.60M | 2.84M | 3.73M | 2.26M |
| Free Cash Flow | - | -52.6M | -32.4M | -74.8M | -42.4M | -34.8M | -27.6M | -47.8M | 8.52M | 1.11M | -5.87M |
| Ratios | |||||||||||
| ROE | -108.9% | -155.6% | -68.1% | -124.9% | -57.7% | -64.3% | -63.3% | -71.2% | -37.3% | -24.3% | -9.0% |
| ROA | -60.8% | -61.7% | -35.2% | -43.0% | -27.0% | -22.9% | -19.6% | -19.0% | -10.4% | -7.0% | -3.3% |
| Net Profit Margin | -160.2% | -118.0% | -75.7% | -76.0% | -52.4% | -34.1% | -26.4% | -24.0% | -11.6% | -7.6% | -3.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Cerus Corporation dividends
Cerus Corporation has not paid dividends in the last 9 fiscal years.
Who owns Cerus Corporation
- Insiders 3.61%
- Institutions 75.05%
- Public & others 21.35%
- Shares outstanding 202M
- Free float 196M
Cerus Corporation company profile
- Company name
- Cerus Corporation
- Ticker
- CU2.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 261
- Fiscal year end
- December
- Address
- 1220 Concord Avenue, Concord, CA, United States, 94520
- Phone
- 925 288 6000
- Website
- cerus.com
About Cerus Corporation
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996. The company was incorporated in 1991 and is headquartered in Concord, California.
Cerus Corporation management
9- Mr. William M. GreenmanExecutive Chairman of the Board · born 1967
- Mr. Vivek K. JayaramanCEO, President & Director · born 1975
- Mr. Kevin D. Green CPAVP of Finance & CFO · born 1972
- Ms. Chrystal N. Jensen J.D.Chief Legal Officer, General Counsel & Secretary · born 1971
- Dr. Richard J. Benjamin MBChB, Ph.D.Chief Medical Officer · born 1960
- Mr. Timothy J. LeeHead of Investor Relation
- Ms. Lainie CortenVice President of Corporate Strategy, Planning & Communications
- Dr. Nina Mufti Ph.D.Senior VP of Research & Development
- Mr. Christian BoutemyVP & MD of Cerus International